INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,
MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)
ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XIV, Issue XI, November 2025
comparing two independent observations and the outcomes of their respective assessments for the same disease
will be discussed. . Further, AUC scores are usually treated as the convenient way to compare multiple
classifiers. Nonetheless, it is also important to check the actual curves especially when evaluating the final
model. In the ROC curve analysis, the choice of the optimal cutoff value depends both on probabilistic and
clinical considerations. From a probabilistic standpoint, one can use the coordinates of the ROC curve to identify
the cutoff that maximizes the discrimination between true-positive rate and false-positive rate.
In this section, a real data scenario is considered to exhibit the practical applicability of comparing two
independent ROC curves. Breast Cancer is one of the chronic diseases, which is rapidly growing and noticed
among women population across the world. Although the survival rate of breast cancer patients has improved,
survival remains poor for advanced stage patients, especially for patients with locally advanced breast cancer.
Simulated data similar to the outcome response measures from a randomized, open-label, clinical study with
indication as Metastatic Breast Cancer was considered. This simulated data has been utilized to study the
patterns and the differences in the evaluations of the independent radiologists’ observations. Several methods
used to evaluate the chemotherapeutic response of breast cancer patients however, MRI is accepted as the best
imaging modality for monitoring the response to NAC. Specific reports have shown that dynamic contrast-
enhanced MRI can reflect the tumor pathophysiologic response to NAC before any changes occur in the tumor
volume.
Two sets of response evaluation criteria have been considered for solid tumors; the response evaluation criteria
in solid tumor is based on (RECIST) criteria. This criteria helped to convert radiologic imaging observations
into a quantitative assessment of a tumor’s response to therapy. The assessments per RECIST criteria were
obtained from two independent investigator assessments. The assessment reports had included the following:
(a) the measurements of the lesions and the count
(b) assessment of pathologic lymph nodes
(c) criteria for disease progression and definition for minimal diameter
(d) Comments on new lesions included in the target lesions.
The aim of this study is to compare the performance of both assessments and evaluating the response of breast
cancer patients to evaluate the differences, if any. To evaluate efficacy and safety of a generic recombinant
human monoclonal antibody(MAB) as treatment therapy in patients with Metastatic Breast Cancer. Evaluations
and outcomes of the treatment were recorded indicating the onset of a PR or CR was done at the end of 6 months.
The primary end point of the study was to assess efficacy as Objective Response Rate (Complete Response and
Partial Response) assessed by the criteria
Tumor response and lesions were categorized into target lesions and non-target lesions and new lesions were
evaluated by CT scan. Two Independent assessor’s verified the assessments) of tumor response and based on
the subjects overall response final assessment were considered for evaluation of efficacy.
The outcomes from the data included 72 patients with a pathologically proven diagnosis of locally advanced
breast cancer, who were treated between May 2013and May 2014. Patients ranged in age from 28 to 63 years,
with the mean age of 49.0 ± 9.6 years.
STATISTICAL METHODS AND DISCUSSIONS
Two radiologists, who were experienced in evaluating radiological finding of the breast and unaware of the
Histopathological outcomes, interpreted all the cases in this study. According to RECIST criteria a lymph node
with a short axis were considered measurable, and these lymph nodes were assessed as target lesions. A
maximum of two target lesions were assessed. The longest diameter of tumor masses or the short axis of lymph
nodes were measured. After chemotherapy, the longest diameter of the tumor and the short axis of the visible
Page 464